$3.055
+0.119 (+3.91%)At close
PBM Comparative Benchmarking
In the context of the broader market, PBM competes directly with industry leaders such as HIND and BOLT. With a market capitalization of $11.64M, it holds a significant position in the sector. When comparing efficiency, PBM's gross margin of N/A stands against HIND's 33.57% and BOLT's 100.00%. Such benchmarking helps identify whether Psyence Biomedical Ltd is trading at a premium or discount relative to its financial performance.
Psyence Biomedical Ltd Financial Performance
The financial performance shows a net income of 141,473 USD in Q3 2025, but a significant loss of -753,254 USD in Q2 2026. The current ratio is 8.09, indicating good short-term liquidity, but the debt-to-equity ratio is concerning at -199.26% in Q3 2025, suggesting financial instability.
Financials
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.